EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Transthyretin Amyloid Cardiomyopathy—2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options

Carsten Tschöpe iD, Ahmed Elsanhoury, Arnt V Kristen

Journal of Clinical Medicine · 07.07.2025 · 14 (13) · 4785

DOI: 10.3390/jcm14134785 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.07.2025. Verfasst von Carsten Tschöpe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology, and Intensive Medicine (CVK), German Heart Center at Charité (DHZC), Charité-University Medicine Berlin, 13353 B…. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transthyretin-related (ATTR) amyloidosis is a progressive, multisystem disease caused by the extracellular deposition of misfolded transthyretin (TTR) monomers as insoluble amyloid fibrils. Clinical manifestations vary widely and may include cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN), or mixed phenotypes. The condition is increasingly recognized as an underdiagnosed contributor to heart failure, particularly in elderly patients. ATTR amyloidosis exists in two major forms: hereditary (ATTRv), resulting from mutations in the TTR gene, and wild-type (ATTRwt), typically affecting men over 70 years of age. Advances in disease understanding have led to a paradigm shift in management, with the introduction of targeted therapies that slow disease progression and improve prognosis. First-generation therapies such as tafamidis have demonstrated survival benefits in ATTR-CM. More recently, second-generation agents—such as the TTR stabilizer acoramidis and RNA silencers including vutrisiran and eplontersen—have shown promising efficacy in clinical trials. Additional strategies under investigation include gene editing and monoclonal antibodies targeting TTR amyloid deposits. This review outlines current diagnostic strategies and therapeutic options for ATTR amyloidosis, emphasizing the need for early detection and individualized treatment approaches. The expanding therapeutic landscape highlights the importance of accurate phenotyping and timely intervention to optimize clinical outcomes.

Schlagwörter

Stichwörter der Autor:innen

ATTR cardiomyopathyATTR polyneuropathyamyloidosisantisense oligonucleotidecardiac amyloidosisclinical developmentgene editingsiRNAtransthyretin

Autor:innen und Institutionen

  • Department of Cardiology, Angiology, and Intensive Medicine (CVK), German Heart Center at Charité (DHZC), Charité-University Medicine Berlin, 13353 Berlin, Germany.
  • Berlin Institute of Health (BIH), Center for Regenerative Therapies (BCRT), Charité-University Medicine Berlin, 13353 Berlin, Germany.
  • Amyloidosis Center, Charité-Universitätsmedizin Berlin (ACCB), Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
  • German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, 13353 Berlin, Germany.
  • Department of Cardiology, Angiology and Respiratory Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • Kardiovaskuläres Zentrum Darmstadt, 64287 Darmstadt, Germany.

ORCID-Profile: Carsten Tschöpe

Zitieren

APA

Tschöpe, C., Elsanhoury, A., & Kristen, A. V. (2025). Transthyretin Amyloid Cardiomyopathy—2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. Journal of Clinical Medicine, 14(13), 4785. https://doi.org/10.3390/jcm14134785

Vancouver

Tschöpe C, Elsanhoury A, Kristen AV. Transthyretin Amyloid Cardiomyopathy—2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. Journal of Clinical Medicine. 2025;14(13):4785. doi:10.3390/jcm14134785

BibTeX
@article{Tschpe2025,
  author = {Tschöpe, Carsten and Elsanhoury, Ahmed and Kristen, Arnt V},
  title = {Transthyretin Amyloid Cardiomyopathy—2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {13},
  pages = {4785},
  doi = {10.3390/jcm14134785}
}
Kostenlos starten →